Clinical trial of OLX301D in age related macular degeneration
Latest Information Update: 05 Oct 2021
At a glance
- Drugs OLX 301D (Primary)
- Indications Dry age-related macular degeneration; Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors OliX Pharmaceuticals
- 05 Oct 2021 New trial record
- 24 Sep 2021 According to an Olix pharmaceuticals media release, Company expects to initiate clinical trials for OLX 301D in 2022.